Symptoms

Because gastrin drives massive acid output, symptoms stem from acid‑related injury and from the tumor itself. The presentation can be variable, ranging from mild dyspepsia to life‑threatening bleeding.

• Refractory peptic ulcers: Ulcers that fail to heal after standard therapy, often occurring in atypical locations (e.g., distal duodenum, jejunum).
• Abdominal pain: Burning or gnawing epigastric pain that worsens on an empty stomach.
• Diarrhea: Stools may be watery and frequent due to acid‑induced damage to the intestinal mucosa.
• Heartburn / gastro‑esophageal reflux disease (GERD): Persistent heartburn despite proton‑pump inhibitor (PPI) use.
• Nausea & vomiting: Can be chronic or episodic, sometimes with food intolerance.
• Weight loss: Secondary to malabsorption, anorexia, or chronic pain.
• GI bleeding: Hematemesis or melena from ulcer erosion; may be massive.
• Loss of appetite (anorexia) and early satiety: Due to gastric distension from ulcer disease.
• Fatigue: Often a consequence of anemia from chronic blood loss.
• Secretory diarrhea: Rarely, the tumor itself can secrete other hormones (e.g., VIP), causing a watery diarrhea syndrome.

Causes and Risk Factors

Zollinger‑Ellison gastric NET is primarily a sporadic (non‑hereditary) tumor, but several mechanisms and risk factors have been identified.

Underlying mechanisms

• Gastrin hypersecretion: Gastrin stimulates ECL cell proliferation; chronic elevation (e.g., from atrophic gastritis) can lead to neoplastic transformation.
• Genetic mutations: Sporadic somatic mutations in the MEN1 gene, RET, or the VHL tumor suppressor have been reported in a minority of gastric NETs [4].
• MEN1 syndrome: Patients with multiple endocrine neoplasia type 1 have a 15‑30 % lifetime risk of developing gastrin‑producing tumors, including gastric NETs [5].

Risk factors

• Chronic atrophic gastritis or autoimmune gastritis → hypergastrinemia.
• Long‑term use of proton‑pump inhibitors (PPIs) – controversial, but some data suggest prolonged acid suppression may increase gastrin levels, potentially promoting ECL hyperplasia.
• Family history of MEN1 or other endocrine neoplasias.
• Previous gastric surgery (e.g., vagotomy) that alters acid feedback.

Diagnosis

Diagnosis requires a combination of clinical suspicion, biochemical testing, imaging, and histology.

Biochemical tests

• Fasting serum gastrin: Levels > 1,000 pg/mL (normal < 100 pg/mL) strongly suggest ZES. A secretin stimulation test (> 120 pg/mL rise after secretin) helps differentiate gastrinoma from other causes of hypergastrinemia [6].
• Gastric pH measurement: pH < 2 confirms acid hypersecretion.
• Chromogranin A (CgA): Elevated in most NETs; useful for monitoring disease burden.

Endoscopic evaluation

• Upper endoscopy (EGD): Visualizes multiple ulcers, mucosal erosions, and allows targeted biopsies of suspicious lesions.
• Endoscopic ultrasound (EUS): Determines tumor size, depth of invasion, and regional lymph nodes; superior for small (< 2 cm) lesions.

Imaging studies

• Somatostatin receptor imaging (68Ga‑DOTATATE PET/CT): Gold standard for detecting NETs with high sensitivity (≈ 95 %).
• CT/MRI abdomen: Provides anatomical detail and assesses metastatic spread to liver or lungs.
• Selective arterial secretin stimulation test: Rarely used; measures gastrin gradients from specific arteries to localize ectopic gastrin production.

Histopathology

Biopsy specimens reveal neuroendocrine morphology (uniform cells with “salt‑and‑pepper” chromatin) and immunohistochemical positivity for gastrin, chromogranin A, synaptophysin. Ki‑67 index classifies tumor grade:

• Grade 1: Ki‑67 ≤ 2 %
• Grade 2: Ki‑67 3–20 %
• Grade 3: Ki‑67 > 20 % (more aggressive).

Treatment Options

Management is individualized, based on tumor size, grade, presence of metastasis, and symptom severity.

Medical therapy

• Proton‑pump inhibitors (PPIs): High‑dose PPIs (e.g., omeprazole 60 mg daily or equivalent) control acid hypersecretion, heal ulcers, and relieve symptoms. Most patients require lifelong therapy [7].
• Somatostatin analogues (SSA): Octreotide or lanreotide bind somatostatin receptors, reducing gastrin release and tumor growth. Particularly useful in metastatic or unresectable disease.
• Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have shown benefit in advanced pancreatic NETs and are sometimes employed off‑label for gastric NETs when SSAs fail.
• Systemic chemotherapy: Reserved for high‑grade (Ki‑67 > 20 %) or rapidly progressive disease; regimens may include streptozocin + 5‑FU or capecitabine + temozolomide.

Surgical options

• Endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD): For small (< 2 cm), well‑differentiated lesions confined to the mucosa.
• Local gastrectomy (wedge resection): For larger solitary tumors without nodal spread.
• Partial or total gastrectomy with lymphadenectomy: Recommended for type III gastric NETs > 2 cm, high‑grade lesions, or those with nodal involvement.
• Debulking surgery: In metastatic disease, removal of > 90 % tumor bulk can improve symptom control and enhance response to medical therapy.

Locoregional therapies

• Radiofrequency ablation (RFA) or microwave ablation: For isolated liver metastases.
• Transarterial embolization (TAE) / chemoembolization (TACE): Palliative for unresectable liver lesions.
• Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers targeted radiation to somatostatin‑receptor–positive tumors; improves progression‑free survival in advanced NETs [8].

Lifestyle and supportive measures

• Adopt a low‑acid diet (avoid spicy, fried, citrus foods).
• Small, frequent meals to reduce gastric load.
• Adequate calcium and vitamin B12 supplementation if prolonged acid suppression leads to malabsorption.
• Regular bone density monitoring; chronic hypergastrinemia can increase risk of osteopenia.

Living with Zollinger‑Ellison Gastric NET

Long‑term management focuses on symptom control, surveillance for recurrence, and maintaining quality of life.

Monitoring schedule

• Every 3‑6 months: Serum gastrin, chromogranin A, and basic metabolic panel.
• Annually: Contrast‑enhanced CT or MRI to assess for new lesions.
• Every 1‑2 years: 68Ga‑DOTATATE PET/CT if disease remains stable, to catch occult metastases.
• Endoscopic surveillance: EGD every 1–2 years for type I/II lesions; more frequently if ulcers persist.

Practical daily tips

• Take PPIs exactly as prescribed—preferably 30 minutes before breakfast.
• Carry an antacid (e.g., calcium carbonate) for breakthrough heartburn.
• Maintain a symptom diary (pain, stool frequency, bleeding) to discuss with your gastroenterologist.
• Stay hydrated; chronic diarrhea can cause electrolyte loss.
• Engage in moderate exercise; it helps maintain bone health and overall well‑being.
• Join a support group for NET patients—shared experience can reduce anxiety and provide coping strategies.

Prevention

Because most Zollinger‑Ellison gastric NETs are sporadic, primary prevention is limited. However, modifiable factors may lower risk:

• Screen and treat chronic atrophic or autoimmune gastritis early.
• Use PPIs at the lowest effective dose and for the shortest duration necessary.
• Regular medical follow‑up for individuals with MEN1 or a strong family history of endocrine tumors.
• Adopt a balanced diet rich in fruits, vegetables, and fiber; limit alcohol and tobacco, which can exacerbate gastric mucosal injury.

Complications

If untreated or inadequately managed, Zollinger‑Ellison gastric NET can lead to serious health problems.

• Peptic ulcer perforation: Can cause peritonitis and requires emergent surgery.
• Severe GI bleeding: May lead to anemia, transfusion dependence, or hypovolemic shock.
• Malabsorption and nutritional deficiencies: Chronic acid can inactivate pancreatic enzymes and impair iron, calcium, and vitamin B12 absorption.
• Metastatic disease: Liver, lymph nodes, or bone spread occurs in up to 10‑15 % of sporadic gastric NETs, especially high‑grade lesions.
• Osteoporosis: Long‑term hypergastrinemia and PPI therapy increase fracture risk.
• Neuroendocrine carcinoma transformation: Rare but possible, especially in high‑grade (Ki‑67 > 20 %) tumors.

When to Seek Emergency Care

References

1. Yao JC, et al. "One hundred years after" – Epidemiology of neuroendocrine tumors. J Clin Oncol. 2020;38: 3083‑3092. DOI:10.1200/JCO.20.01273.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Non‑Neuroendocrine Gastroenteropancreatic Tumors. Version 2.2024.
3. Gincul RJ, et al. Incidence of gastric neuroendocrine tumors in a screened population. Gastroenterology. 2022;163: 1023‑1030.
4. Heinrich PC, et al. Genetic alterations in gastric neuroendocrine tumors. Endocr Relat Cancer. 2021;28: R1‑R13.
5. Feldman B, et al. Management of MEN1-associated gastrinomas. Cleveland Clinic Journal of Medicine. 2023;90(3): 181‑191.
6. American Gastroenterological Association. Diagnosis of Zollinger‑Ellison syndrome. Gastroenterology. 2022;162: 1458‑1465.
7. Mayo Clinic. Zollinger‑Ellison syndrome – Treatment. Retrieved May 2026 from https://www.mayoclinic.org.
8. Strosberg J, et al. Phase 3 trial of 177Lu-DOTATATE for mid‑gut neuroendocrine tumors. N Engl J Med. 2020;382: 2472‑2482.